|Bid||174.07 x 200|
|Ask||174.11 x 300|
|Day's Range||170.83 - 174.54|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.53|
|Dividend & Yield||4.60 (2.65%)|
|1y Target Est||N/A|
July isn't a great month for the stock market historically, but these stocks tend to perform well.
Denodo Technologies Inc.’s founder and senior management team will retain an ownership stake in the company.
In biotech, investors are always looking for the next big thing, or at least the next thing. Which is one reason Amgen's (AMGN) Erenumab is being closely watched by analysts. Amgen submitted the data for the treatment of migraines by erenumab to the FDA in May. And Oppenheimer's Leah Rush Cann, who rates Amgen Outperform, argues that Erenumab will "be adopted for treatment of migraine quickly after launch." She explains why: Our report Migraine Survey, June 27, 2017, supports our view that Erenumab will be adopted for treatment of migraine quickly after launch.